Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Lilly's first Phase 3 readout (TRIUMPH4) reported strong results in people with obesity/overweight and knee osteoarthritis, including: ~28.7% average weight loss at 68 weeks at the 12 mg dose (topline reporting), plus improvements in pain and function measures The important phrase there is "topline"
The honest answer is that it depends on the indication, and the timeline varies enough between tissue types that a single number is misleading
The rate of gastric emptying during OGTT was assessed after 4 and 8 weeks of treatment (Fig
Thats why a supportive plan with nutrition, exercise, and coaching is critical during and after treatment
In 2021, the FDA stamped its approval on high-dose semaglutide under the brand name Wegovy, officially giving doctors a new heavyweight contender for chronic weight management
US$ 27.08
US$ 24.74
US$ 29.05
US$ 23.25
US$ 29.04
